参考文献/References:
[1] 李春霞,兰春慧.肝动静脉瘘的研究进展[J].国际消化病杂志,2014,34:238-240.
Li CX,Lan CH.Research progress of hepatic arteriovenous fistula[J].International Journal of Digestive Diseases,2014,34:238-240.
[2]李顺宗,李智岗,赵俊京.肝癌合并动静脉瘘的DSA表现及介入治疗方法的探讨[J].实用放射学杂志,2005,21:854-857.
Li SZ,Li ZG,Zhao JJ.DSA findings and interventional therapy of hepatocellular carcinoma with arteriovenous fistula[J].J Pract Radiol,2005,21:854-857.
[3]曹斗斗.数字减影血管造影技术在肝癌合并肝动脉-门静脉瘘介入治疗中的应用[J].当代医学,2021,27:127-129.
Cao DD.Application of digital subtraction angiography in interventional therapy for hepatocellular carcinoma with hepatic artery-portal vein fistula[J].Contemporary Medicine,2021,27:127-129.
[4]Almaguer J,Khan A,Saleem A.Pre-transarterial radioembolization of tumoral arteriovenous fistula associated with recanalized umbilical vein shunt in a case of hepatocellular carcinoma with hepatic vein and inferior vena cava invasion[J].Cureus,2023,15:e44784.
[5]Panda A,Narayanan D,Netaji A,et al.Spontaneous hepatic arterioportal fistula in extrahepatic portal vein obstruction:Combined endovascular and surgical management[J].Ann Hepatobiliary Pancreat Surg,2023,27:307-312.
[6]Noorbakhsh S,Gomez L,Joung Y,et al.Hepatic arterioportal fistula following liver trauma:Case series and review of the literature[J].Vasc Endovascular Surg,2023,57:749-755.
[7]Craig E V,Heller M T.Complications of liver transplant[J].Abdom Radiol(NY),2021,46:43-67.
[8]Pupulim L F,Terraz S,Spahr L.Intrahepatic pseudoaneurysm with arteriovenous fistula after transjugular liver biopsy[J].Liver Int,2023,43:2824-2825.
[9]Choi J W,Lee J M,Kim H C,et al.Iatrogenic arterioportal fistula caused by radiofrequency ablation of hepatocellular carcinoma:Clinical course and treatment outcomes[J].J Vasc Interv Radiol,2020,31:728-736.
[10]Shimose S,Iwamoto H,Tanaka M,et al.Increased arterio-portal shunt formation after drug-eluting beads TACE for hepatocellular carcinoma[J].Oncology,2020,98:558-565.
[11]Yuan GS,Zhang LL,Chen ZT,et al.Comparison of ethanol-soaked gelatin sponge and microspheres for hepatic arterioportal fistulas embolization in hepatic cellular carcinoma[J].World J Gastrointest Oncol,2023,15:1595-1604.
[12]陈水兵,贺 辉,金诗湘,等.原发性肝癌合并肝动静脉瘘患者经导管动脉化疗栓塞后早期联合射频消融治疗的临床研究[J].中国现代医学杂志,2023,33:51-55.
Chen SB,He H,Jin SX,et al.Combined transcatheter arterial chemoembolization and early radiofrequency ablation for hepatocellular carcinoma with hepatic arteriovenous fistula:A clinical study[J].China Journal of Modern Medicine,2023,33:51-55.
[13]张东东,张明顼,孙立倩.肝动脉化疗栓塞联合微波消融术治疗原发性肝癌合并动静脉瘘的临床疗效[J].中国医疗设备,2022,37:569-570.
Zhang DD,Zhang MX,Sun LQ.Clinical efficacy of transcatheter arterial chemoembolization combined with microwave ablation for hepatocellular carcinoma with arteriovenous fistula[J].China Medical Devices,2022,37:569-570.
[14]Zhan H,Zhao X,Lu Z,et al.Correlation and survival analysis of distant metastasis site and prognosis in patients with hepatocellular carcinoma[J].Front Oncol,2021,11:652768.
[15]方 瑜,龙清云,刘骏方,等.肝癌合并肝动脉-肝门静脉瘘介入治疗方式的探讨[J].介入放射学杂志,2010,19:776-779.
Fang Y,Long QY,Liu JF,et al.Interventional treatment approaches for hepatocellular carcinoma with hepatic artery-portal vein fistula[J].J Interv Radiol,2010,19:776-779.
[16]吴金棉,罗骏阳,梁炎辉,等.门脉血流对PHT患者肝功能及预后评估价值[J].医学理论与实践,2022,35:2809-2812.
Wu JM,Luo JY,Liang YH,et al.The value of portal vein blood flow for liver function and prognosis assessment in portal hypertension patients[J].Journal of Medical Theory and Practice,2022,35:2809-2812.
[17]李莹莹,罗二平,段云友,等.多普勒超声在原发性肝癌肝动-静脉瘘检测中的应用[J].第四军医大学学报,2006,13:1223-1226.
LI YY,Luo EP,Duan YY,et al.Application of Doppler ultrasound in detection of hepatic arteriovenous fistula in hepatocellular carcinoma[J].Journal of the Fourth Military Medical University,2006,13:1223-1226.
[18]Choi BI,Lee KH,Han JK,et al.Hepatic arterioportal shunts:dynamic CT and MR features[J].Korean J Radiol,2002,3:1-15.
[19]姚宏亮,胡道予,汪建成.MSCT和DSA对原发性肝癌的影像诊断价值的对照[J].放射学实践,2006,21:85-88.
Yao HL,Hu DY,Wang JC.Comparative study of MSCT and DSA in imaging diagnosis of hepatocellular carcinoma[J].Radiologic Practice,2006,21:85-88.
[20]徐宏伟,徐风峰,刘奕青,等.多层螺旋CT对肝癌合并肝动静脉瘘的诊断价值[J].中国医学影像技术,2003,19:432-434.
Xu HW,Xu FF,Liu YQ,et al.Diagnostic value of multislice spiral CT in hepatocellular carcinoma with hepatic arteriovenous fistula[J].Chinese Journal of Medical Imaging Technology,2003,19:432-434.
[21]于长鹿.肝癌合并动静脉瘘的影像诊断及介入治疗[J].生物医学工程与临床,2009,13:71-75.
Yu CL.Imaging diagnosis and interventional therapy of hepatocellular carcinoma with arteriovenous fistula[J].Biomedical Engineering and Clinical Medicine,2009,13:71-75.
[22]Bakri S J,Lynch J,Howard-sparks M,et al.Vorolanib,sunitinib,and axitinib:a comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects[J].PLoS One,2024,19:e0304782.
[23]Leong A,Kim M.The Angiopoietin-2 and TIE Pathway as a therapeutic target for enhancing antiangiogenic therapy and immunotherapy in patients with advanced cancer[J].Int J Mol Sci,2020,21:86-89.
[24]Vanderborght B,Lefere S,Vierberghe H V,et al.The Angiopoietin/Tie2 pathway in hepatocellular carcinoma[J].Cells,2020,9:2382.
[25]Lee E,Lee E A,Kong E,et al.An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone[J].Exp Mol Med,2023,55:470-484.
[26]Meo C,De Nigris F.Clinical potential of YY1-Hypoxia axis for vascular normalization and to improve immunotherapy[J].Cancers(Basel),2024,16:491.
[27]Yang F,Lee G,Fan Y.Navigating tumor angiogenesis:therapeutic perspectives and myeloid cell regulation mechanism[J].Angiogenesis,2024,27:333-349.
[28]Liu Y,Gong L,Feng J,et al.Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity[J].J Nanobiotechnology,2025,23:194.
[29]Zalpoor H,Aziziyan F,Liaghat M,et al.The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors[J].Cell Commun Signal,2022,20:186.
[30]Wachholz G E,Akbari P,Huijbers E J M,et al.Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors[J].Biochim Biophys Acta Rev Cancer,2024,1879:189155.
[31]Huang X,Guan J,Sheng Z,et al.Effect of local anti-vascular endothelial growth factor therapy to prevent the formation of stenosis in outflow vein in arteriovenous fistula[J].J Transl Int Med,2021,9:307-317.
[32]Han Z,Han R,Wang Y,et al.Sorafenib combined with TACE improves survival in patients with hepatocellular carcinoma with vascular invasion[J].Biosci Trends,2024,18:457-464.
[33]Kim G H,Choi S L,Kim J H,et al.Sorafenib combined with chemoembolization for locally advanced hepatocellular carcinoma with macroscopic vascular invasion:A propensity score analysis[J].Life(Basel),2021,11:1066.
[34]Chen Q,Sun Q,Zhang J,et al.Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma[J].PLoS One,2024,19:e0295090.
[35]邱作栋,余会丽,户军燕,等.信迪利单抗联合贝伐珠单抗治疗不可切除肝细胞肝癌的疗效及安全性[J].实用癌症杂志,2023,38:2034-2037.
Qiu ZD,Yu HL,Hu JY,et al.Efficacy and safety of sintilimab combined with bevacizumab in the treatment of unresectable hepatocellular carcinoma[J].The Practical Journal of Cancer,2023,38:2034-2037.
[36]涂江江,赵燕仪,石援援,等.信迪利单抗加贝伐珠单抗联合经肝动脉化疗栓塞术治疗晚期肝癌的临床研究[J].中国医药,2025,20:216-220.
Tu JJ,Zhao YY,Shi YY,et al.Clinical study of sintilimab plus bevacizumab combined with transarterial chemoembolization for advanced hepatocellular carcinoma[J].China Medicine,2025,20:216-220.
[37]惠 锋,马守成,裴霞霞.信迪利单抗、贝伐珠单抗联合肝动脉化疗栓塞术在中晚期肝癌患者中的临床应用[J].中国现代医学杂志,2024,34:86-91.
Hui F,Ma S C,Pei X X.Clinical application of sintilimab and bevacizumab combined with transarterial chemoembolization in patients with intermediate-advanced hepatocellular carcinoma[J].China Journal of Modern Medicine,2024,34:86-91.
[38]李素素,马曾庆,吴连平,等.贝伐珠单抗致严重不良反应30例文献分析[J].临床合理用药,2025,18:152-155.
Li SS,Ma ZQ,Wu LP,et al.Literature analysis of 30 cases of severe adverse reactions induced by bevacizumab[J].Clinical Rational Drug Use,2025,18:152-155.
[39]Kaibori M,Matsushima H,Ishizaki M,et al.The impact of sorafenib in combination with intermittent hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with major vascular invasion[J].Cancer Invest,2022,40:81-89.
[40]Nomura T,Tani J,Deguchi A,et al.Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion[J].Mol Clin Oncol,2019,11:447-454.
[41]Kikuchi H,Matsui A,Morita S,et al.Increased CD8+ T-cell infiltration and efficacy for multikinase inhibitors after PD-1 blockade in hepatocellular carcinoma[J].J Natl Cancer Inst,2022,114:1301-1305.
[42]Winograd P,Hou S,Court C M,et al.Hepatocellular carcinoma-circulating tumor cells expressing PD-L1 are prognostic and potentially associated with response to checkpoint inhibitors[J].Hepatol Commun,2020,4:1527-1540.
[43]Merle P,Kudo M,Edeline J,et al.Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma:longer term follow-up from the Phase 3 KEYNOTE-240 trial[J].Liver Cancer,2023,12:309-320.
[44]Abou-Alfa GK,Lau G,Kudo M,et al.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J].NEJM Evid,2022,1:EVIDoa2100070.
[45]Kudo M.Nivolumab plus Ipilimumab:a novel first-Line combination immunotherapy for unresectable hepatocellular carcinoma[J].Liver Cancer,2024,13:459-467.
[46]Dudzinska M,Szczyrek M,Wojas-Krawczyk K,et al.Endocrine adverse events of nivolumab in non-small cell lung cancer patients-literature review[J].Cancers(Basel),2020,12:2314.
[47]Huang Y,Goel S,Duda D G,et al.Vascular normalization as an emerging strategy to enhance cancer immunotherapy[J].Cancer Res,2013,73:2943-2948.
[48]Tian L,Goldstein A,Wang H,et al.Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming[J].Nature,2017,544:250-254.
[49]Zhu AX,Abbas AR,De Galarreta MR,et al.Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma[J].Nat Med,2022,28:1599-1611.
[50]Roessler D,Ocal O,Philipp A B,et al.Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies:a multicenter retrospective study[J].J Cancer Res Clin Oncol,2023,149:3065-3073.
[51]Choi WS,Yoon CJ,Lee JH,et al.Hepatic artery embolization for postoperative hemorrhage:importance of arterial collateral vessels and portal venous impairment[J].J Vasc Interv Radiol,2021,32:826-834.
[52]Li D,Toh H C,Merle P,et al.Atezolizumab plus Bevacizumab versus Sorafenib for unresectable hepatocellular carcinoma:Results from older adults enrolled in the IMbrave150 randomized clinical trial[J].Liver Cancer,2022,11:558-571.
[53]陈嘉楠,丁文龙,朱思遥,等.贝伐珠单抗治疗恶性腹腔积液的研究进展[J].临床肿瘤学杂志,2022,27:172-177.
Chen JN,Ding WL,Zhu SY,et al.Research progress on Bevacizumab in the treatment of malignant ascites[J].Chinese Journal of Clinical Oncology,2022,27:172-177.
[54]Liu X,Lu Y,Zhou W,et al.Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma(2023 Edition)[J].Liver Cancer,2024,13:355-375.
[55]Yu Q,Thapa N,Karani K,et al.Transarterial radioembolization versus transarterial chemoembolization plus percutaneous ablation for unresectable,solitary hepatocellular carcinoma of ≥3 cm:A propensity score-matched study[J].J Vasc Interv Radiol,2022,33:1570-1577.
[56]Chen L,Zhang W,Sun T,et al.Effect of transarterial chemoembolization plus percutaneous ethanol injection or radiofrequency ablation for liver tumors[J].J Hepatocell Carcinoma,2022,9:783-797.
[57]Fei J,Qi LW,Liu Y,et al.Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment[J].World J Gastrointest Oncol,2025,17:102038.
[58]Feray C,Canpion L,Mathurin P,et al.TACE and conformal radiotherapy vs.TACE alone for hepatocellular carcinoma:a randomised controlled trial[J].JHEP Rep,2023,5:100689.
[59]Cai Z,Ran M,Song J,et al.Imaging diagnosis and interventional treatment for hepatocellular carcinoma combined with arteriovenous fistula[J].J Healthc Eng,2021,2021:6651236.
[60]Cai L,Li H,Guo J,et al.Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula[J].Cancer Biol Ther,2022,23:89-95.
[61]武中林,吴勇超,荣小翠,等.原发性肝癌经导管肝动脉灌注化疗栓塞所致急性肝损伤的最优保肝方案筛选[J].中国全科医学,2019,22:3159-3164.
Wu ZL,Wu YC,Rong XC,et al.Optimal hepatoprotective regimen selection for acute liver injury induced by transcatheter hepatic arterial chemoembolization in primary hepatocellular carcinoma[J].Chinese General Practice,2019,22:3159-3164.
[62]Selzman J,Gajendran M,El Kurdi B,et al.Transarterial chemoembolization-induced ischemic colitis:a rare complication due to nontarget embolization[J].ACG Case Rep J,2023,10:e01140.
[63]徐国斌,熊 斌,刘骏方,等.原发性肝癌合并肝动静脉瘘的介入栓塞治疗策略及疗效探讨[J].临床放射学杂志,2011,30:82-85.
Xu GB,Xiong B,Liu JF,et al.Interventional embolization strategies and therapeutic efficacy for hepatocellular carcinoma with hepatic arteriovenous fistula[J].Journal of Clinical Radiology,2011,30:82-85.
[64]李 凯,刘瑞宝.原发性肝癌所致肝动静脉瘘的介入治疗现状[J].中国医药导报,2012,9:23-25.
Li K,Liu RB.Current status of interventional therapy for hepatic arteriovenous fistula caused by hepatocellular carcinoma[J].China Medical Herald,2012,9:23-25.
[65]陈彦晖,张玉冰,尹韵清,等.HAIC在不可切除肝癌合并高流量肝动脉门静脉瘘的短期疗效及安全性[J].肝胆胰外科杂志,2024,36:144-149.
Chen YH,Zhang YB,Yin YQ,et al.Short-term efficacy and safety of HAIC for unresectable hepatocellular carcinoma with high-flow hepatic artery-portal vein fistula[J].Journal of Hepatopancreatobiliary Surgery,2024,36:144-149.
[66]杜 楠,王 英,李文涛.肝癌TACE还是HAIC?[J].介入放射学杂志,2024,33:1269-1273.
Du N,Wang Y,Li WT.TACE or HAIC for hepatocellular carcinoma?[J].J Interv Radiol,2024,33:1269-1273.
(收稿日期:2025-03-19)
(本文编辑:新 宇)
相似文献/References:
[1]曹海利,孟巍,白彬.肝癌基因治疗研究新进展[J].介入放射学杂志,2008,(05):375.
CAO Haili,MENG Wei,BAI Bin.New progress in research of gene therapy for hepatocellular carcinoma[J].J Intervent Med,2008,(03):375.
[2]陆骊工,胡宝山,李勇,等.中晚期原发性肝癌合并症的介入治疗研究[J].介入放射学杂志,2008,(07):514.
LU Ligong,HU Baoshan,LI Yong,et al.Study of interventional therapy for complications in advanced primary hepatocellular carcinoma[J].J Intervent Med,2008,(03):514.
[3]杨伟洪,刘鹏程,梁珊瑚,等.多层螺旋CT血管造影在判断肝癌寄生供血中的价值[J].介入放射学杂志,2008,(09):654.
YANG Weihong,LIU Pengchen g,LIANG Shanhu,et al.Evaluation of MSCTA for parasitic blood supply in hepatic carcinoma[J].J Intervent Med,2008,(03):654.
[4]张茵,周兵,许秀芳,等.肝动脉化疗栓塞治疗原发性肝癌存活２０年一例[J].介入放射学杂志,2008,(09):684.
ZHANG Yin,ZHOU Bing,XU Xiufang,et al.Survival more than２０years after transarterial chemical embolization for hepatocellular carcinoma：A case report[J].J Intervent Med,2008,(03):684.
[5]官泳松,贺庆.肝癌介入治疗中应用p５３的几个要点[J].介入放射学杂志,2008,(11):761.
GUAN Yongsong,HE Qing.Essentials in clinical application of p５３for tumors intervention－example of liver cancer[J].J Intervent Med,2008,(03):761.
[6]肖运平,肖恩华.介入治疗在防治肝癌术后复发中的作用及进展[J].介入放射学杂志,2008,(11):831.
XIAO Yunping,XIAO Enhua.The role and progress of interventional therapy in the prevention and treatment of postoperative hepatocellular carcinoma recurrence[J].J Intervent Med,2008,(03):831.
[7]史震山,陈自谦,杨熙章,等.原发性大肝癌患者TACE后S－腺苷蛋氨酸的护肝作用[J].介入放射学杂志,2008,(11):790.
SHI Zhenshan,CHEN Ziqian,YANG Xizhang,et al.The clinical study on the liver－protection of S－adenosy－methionine in large hepatocellular carcinoma patients after TACE[J].J Intervent Med,2008,(03):790.
[8]王耀普,杨康健,赵思源,等.兔肝癌模型的改良接种及其DSA影像分析[J].介入放射学杂志,2010,(03):214.
WANG Yaopu,YANG Kangjian,ZHAO Siyuan,et al.The modified inoculation method for the preparation of rabbit VX２hepatic carcinoma model and DSA imagining observation[J].J Intervent Med,2010,(03):214.
[9]贺洪德,贺晶,罗中华,等.肝动脉化疗栓塞联合门静脉栓塞治疗中晚期肝癌的疗效评价[J].介入放射学杂志,2010,(03):191.
HE Hongde,HE Jing,LUO Zhonghua,et al.Evaluation of the therapeutic effect of hepatic arterial chemoembolization combined with portal chemoembolization for advanced hepatic carcinomas[J].J Intervent Med,2010,(03):191.
[10]李广琪,曹玮,李超,等.肝动脉热灌注对兔肝VX２肿瘤及正常肝组织血管渗透性功能的作用[J].介入放射学杂志,2010,(03):217.
LI Guangqi,CAO Wei,LI Chao,et al.Influence of hepatic artery thermotherapy on the vascular permeability of hepatic tumor tissue and normal liver tissue in VX２tumor－bearing rabbits[J].J Intervent Med,2010,(03):217.
[11]李继军,尚建强,刘作勤,等.肝癌肝动脉－门静脉瘘并消化道出血的介入治疗[J].介入放射学杂志,2011,(02):120.
LI Ji-jun,SHANG Jian-qiang,LIU Zuo-qin,et al.Interventional treatment of upper gastrointestinal bleeding in patients of hepatic carcinoma accompanied with hepatic artery-portal vein shunting[J].J Intervent Med,2011,(03):120.